Boston Scientific (NYSE:BSX) Releases Q1 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its first quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.780-0.800 for the period, compared to the consensus estimate of 0.790. The company issued revenue guidance of $5.1 billion-$5.2 billion, compared to the consensus revenue estimate of $5.2 billion. Boston Scientific also updated its FY 2026 guidance to 3.430-3.490 EPS.

Analyst Ratings Changes

Several brokerages recently issued reports on BSX. Morgan Stanley lifted their price objective on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Wells Fargo & Company raised their price target on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Thursday, January 15th. Royal Bank Of Canada increased their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Barclays dropped their target price on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $123.26.

Boston Scientific Trading Down 15.4%

Shares of NYSE:BSX traded down $14.14 during trading on Wednesday, reaching $77.48. The stock had a trading volume of 34,552,151 shares, compared to its average volume of 13,667,540. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The stock has a market cap of $114.85 billion, a P/E ratio of 41.42, a PEG ratio of 1.63 and a beta of 0.67. The business has a fifty day moving average price of $94.89 and a 200-day moving average price of $99.29. Boston Scientific has a fifty-two week low of $75.00 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 191,105 shares of company stock worth $18,067,697. 0.50% of the stock is currently owned by insiders.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat: BSX posted $0.80 EPS vs. $0.78 consensus and reported 15.9% year-over-year net sales growth — confirms underlying demand and operational momentum. Zacks: Boston Scientific Beats Q4
• Positive Sentiment: Revenue detail: net sales ~$5.29B with ~12.7% organic growth — supports medium-term revenue base and validates product momentum across several franchises. PR Newswire: Q4 Results
• Neutral Sentiment: Analyst backdrop: many firms still rate BSX a Buy with mid- to high‑teens upside targets — consensus remains constructive despite near-term headwinds. MarketBeat: Analyst Consensus
• Negative Sentiment: Soft 2026 guidance: management issued modest revenue growth and profit guidance that trailed Street expectations, which was the primary driver of the early selloff. WSJ: Profit, Sales Rise but Issues Soft Guidance
• Negative Sentiment: Electrophysiology weakness: management called out light EP sales (one of its key growth drivers), raising near-term execution concerns. Blockonomi: Why Shares Dropped
• Negative Sentiment: Market positioning and sentiment: unusually large put-option buying (≈23,490 puts, ~52% above average) indicates elevated bearish hedging/speculation adding downward pressure.
• Negative Sentiment: Insider sale: CEO Michael Mahoney sold ~160,901 shares (~$15M) last week; such a large disclosed sale can amplify negative sentiment even if preplanned. SEC Filing: Insider Sale

Institutional Investors Weigh In On Boston Scientific

Institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the last quarter. First Foundation Advisors acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at about $237,000. Ausdal Financial Partners Inc. bought a new position in shares of Boston Scientific during the third quarter worth about $281,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in Boston Scientific in the third quarter worth about $328,000. Finally, Seven Mile Advisory grew its stake in Boston Scientific by 26.4% in the third quarter. Seven Mile Advisory now owns 3,802 shares of the medical equipment provider’s stock worth $371,000 after purchasing an additional 795 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.